-
A ranar 3 ga Disamba, 2024, Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta amince da maganin Zepzelca (lurbinectedin don allura) don tallatawa ta hanyar shirin bita na fifiko. An yi amfani da maganin don magance manyan marasa lafiya da ke fama da cutar huhu ta ƙananan ƙwayoyin cuta...Kara karantawa»
-
A ranar 31 ga Disamba, Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta amince da VYLOYTM (zolbetuximab), tare da maganin chemotherapy mai ɗauke da fluoropyrimidine da platinum, don maganin farko ga marasa lafiya da suka kamu da cutar epidermal ta ɗan adam wadda ba a iya cirewa ko kuma ta yaɗuwa a cikinta...Kara karantawa»
-
Disamba 31, 2024, Kamfanin Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kamfanin") ya sami izinin tallatawa a China daga Hukumar Kayayyakin Lafiya ta Kasa (NMPA) don maganin ligand1 (PD-L1) wanda aka tsara don maganin rigakafi na monoclonal mai rai ("mAb")...Kara karantawa»
-
C-CAR031 magani ne mai ɗauke da sinadarin antigen na GPC3 mai suna T-Cell (CAR-T) wanda ke ɗauke da sinadarin GPC3, wanda aka yi nazari a kansa don maganin HCC. Ya dogara ne akan wani sabon maganin CAR-T mai suna GPC3 wanda AstraZeneca ta tsara ta amfani da maganin da ke ɗauke da sinadarin beta mai suna II dominant negati...Kara karantawa»
-
A ranar 20 ga Disamba, 2024, Hukumar Kula da Kayayyakin Lafiya ta Kasa (NMPA) ta amince da amfani da sabon magani (NDA) na DOVBLERON® (taletrectinib adipate capsule), wani maganin hana tyrosine kinase na ROS1 (TKI) na zamani, don magance manyan marasa lafiya da suka kamu da cutar ROS ta hanyar da ba ta dace ba ko kuma ta hanyar da ba ta dace ba...Kara karantawa»
-
C-CAR031 magani ne mai ɗauke da sinadarin antigen mai suna T-Cell (CAR-T) wanda ke da alaƙa da GPC3, wanda aka yi nazari a kansa don maganin HCC. An gabatar da ci gaban binciken C-CAR031 a cikin cutar kansar hanta (HCC) a taron shekara-shekara na American Society of Clinical Oncology (ASCO) a ranar 1 ga...Kara karantawa»
-
GT101 magani ne na ƙwayoyin halitta wanda aka yi da TIL da aka faɗaɗa kuma aka sake farfaɗowa daga ciwon majiyyaci. Ana gudanar da maganin ta hanyar tattara ƙwayoyin ciwon daji daga marasa lafiya da kuma cire TIL. Daga nan za a ƙara girman TIL da aka cire ta amfani da dandamalin masana'antu na Grit Bio na StemTe...Kara karantawa»
-
Kwayoyin TAEST16001 ƙwayoyin T ne da aka ƙera ta hanyar halitta waɗanda ke bayyana babban haɗin kai na NY-ESO-1-specific T-cell receptor (TCR) wanda ke nufin NY-ESO-1 (wanda aka bayyana a cikin nau'ikan ciwace-ciwacen) mai kyau ta hanyar sarcoma mai laushi na nama (STS) a cikin mahallin HLA-A*02:01. Wani bincike na mataki na I a cikin marasa lafiya da ke da ciwon suga mai tsanani...Kara karantawa»
-
A ranar 4 ga Disamba, 2024, an ba da izinin amfani da sabon magani (NDA) don haɗa TYVYT® (allurar sintilimab) da ELUNATE® (fruquintinib) a China don maganin marasa lafiya da ke fama da ciwon daji na endometrial mai tsanani tare da ciwon daji na Mismatch Repair proficient (pMMR) waɗanda ke da...Kara karantawa»
-
GC203 wani sabon maganin TIL ne wanda aka gyara kwayar halitta ta hanyar amfani da dandamalin fadada kwayar halitta na DeepTIL® na Juncell Therapeutics da kuma dandamalin gyaran kwayar halitta na NovaGMP®. DeepTIL® yana bawa TILs damar yin karfi sosai har ba za a buƙaci haɗin IL-2 ba bayan jiko, kuma...Kara karantawa»
-
Glioblastoma Multiforme (GBM) yana ɗaya daga cikin cututtukan daji mafi muni, kuma kusan dukkan marasa lafiya suna fuskantar sake dawowa bisa ga tsarin kulawa na yanzu ga sabbin GBM da aka gano. GBM mai maimaitawa (rGBM) yana nuna matsakaicin rayuwa na ƙasa da watanni 8 tare da iyakantaccen zaɓuɓɓukan magani. TX103 shine CAR-T ce...Kara karantawa»
-
RD13-02 samfurin ƙwayoyin CAR-T ne na duniya wanda ke nufin CD7 wanda aka samo daga masu ba da gudummawa masu lafiya, kuma an yi shi ne don maganin cutar sankarar lymphoblastic mai saurin kamuwa da cutar T-cell (T-ALL/LBL) wadda ta sake dawowa ko kuma ta sake yin illa. Ana gyara ta ta hanyar kwayoyin halitta don guje wa cutar fratricide, cutar graft-versus-host (GvHD), da kuma cutar host-versus-...Kara karantawa»
Cibiyar likitanci ta haɗin gwiwa ta Asibitin Ciwon Daji na Beijing